Morgan Stanley Remains a Hold on BioNTech SE (BNTX)

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on BioNTech SE (BNTXResearch Report) today and set a price target of $216.00. The company’s shares opened today at $143.28.

According to TipRanks, Harrison is a 5-star analyst with an average return of 7.9% and a 53.46% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine.

BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $201.38, which is a 40.55% upside from current levels. In a report released on January 16, Goldman Sachs also maintained a Hold rating on the stock with a $177.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BNTX market cap is currently $34.65B and has a P/E ratio of 3.08.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More